Raw Material Management and Control

Summary and Background

All tissue and cell contact materials—including culture media, preservation solutions, containers, and labels—must be quality-controlled and meticulously tracked. Each batch or lot of material must be documented, and in the event of an issue, it must be traceable back to its source for corrective action.

cGTP (current Good Tissue Practice)is a standard that regulates the management of human cell and tissue-based products to ensure safety and quality from donor collection to clinical use.

Often compared to pharmaceutical GMP, cGTP focuses on specific requirements for the handling of human tissues and cell-derived products (HCT/P).

The Acquisition, Processing, Storage, and Delivery Process

These regulations are enforced by regulatory bodies, such as the FDA in the US, to prevent the transmission of diseases through biological products and to ensure safe practices for collection, processing, storage, and distribution.

Tissue collection must be performed aseptically. Immediately following collection, the tissue must be processed under controlled conditions, such as washing, concentration, or appropriate freezing. During storage, temperature and humidity must be monitored and maintained. Shipping must be conducted using a properly maintained temperature-controlled (cold chain) system.

Key Requirements

Quality Control and Product Testing

The core of cGTP isPrevention of infectious disease transmissionRequirements include donor eligibility evaluation, facility environmental control, raw material and reagent management, as well as documentation and tracking throughout the process.

Each production stage must incorporate quality inspections and testing. These include, for instance, sterility testing to ensure the absence of bacteria or fungi, cell count and viability measurements, endotoxin testing, among others. The results of these tests shall be thoroughly documented and evaluated before the product is approved for use or commercialization.

Donor Suitability Evaluation

Documentation and Tracking

Donor screening must include medical history review and laboratory testing to exclude the risk of infectious diseases such as HIV or hepatitis.

All processes shall be documented through written Standard Operating Procedures (SOPs). Records for each batch or lot of product shall include donor information, collection date, test results, storage, and distribution. This comprehensive traceability enables rapid investigation in the event of issues and facilitates product recall if necessary.

Facilities and Environmental Control

Personnel Training and Competence

The facility shall include clean areas and the capability for aseptic operations, including periodic environmental monitoring and equipment maintenance.

All personnel involved in the handling of tissues and cells shall be adequately trained in aseptic procedures, biosafety, and specific cGTP requirements. Training shall be documented, and new personnel shall undergo an orientation program before performing work independently.

Materials and Processes Management

All materials coming into contact with tissue must be quality-controlled and batch-tracked. The collection, processing, storage, and shipping processes must maintain conditions that minimize contamination.

Significance and Benefits of Compliance

Quality Control and Documentation

For Institutions and Medical Facilities

Each step must be documented in accordance with standard operating procedures, with records maintained to facilitate traceability and corrective actions should an anomaly occur.

Adherence to cGTP demonstrates an institution's commitment to safety and quality. This enhances trust among clinical partners, regulators, and, most importantly, patients. cGTP-compliant facilities facilitate international partnerships, streamline regulatory audits, and simplify the process of obtaining certification from international bodies such as AABB or FACT.

In summary, cGTP mitigates the risk of transmission through tissue and cell products by implementing consistent controls across the entire supply chain and manufacturing processes.

For Patients and Recipients

cGTP compliance directly protects patients by reducing the risk of disease transmission through transplantation or cell infusion. Patients who receive tissues or cells from a cGTP-certified facility can be assured that the products have been screened and processed to the highest international safety standards.

Benefits of cGTP Certification

Compliance with cGTP demonstrates a commitment to safety and quality, thereby fostering confidence among clinical partners, regulators, and patients.

Impact on Products, Services, and Consumers

Tissue and cell products processed in accordance with cGTP demonstrate superior quality. This results in a significant reduction in contamination risk, improved cell viability, and enhanced clinical performance. Successful transplantation and cell therapy, achieved with minimal complications, leads to increased patient satisfaction and strengthens public confidence in regenerative medicine and cell therapy.

Furthermore, compliant facilities will be better positioned to participate in international cooperation and receive more favorable assessments during regulatory inspections.

Across the biotechnology and medical sectors, cGTP establishes a safer environment for consumers and drives sustainable innovation in cell therapy and tissue regeneration.

Organizational and Regulatory Affairs

While cGTP is a concept pioneered by the U.S. FDA, its principles are shared internationally and are relevant to guidance from bodies such as the WHO, and to certification standards from organizations like AABB and FACT.

International Organizations and Related Regulatory Bodies